Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

August 13, 2025

Roughly Half of Patients Don’t Have Symptoms Prior to a First MI

News Daily News

Roughly Half of Patients Don’t Have Symptoms Prior to a First MI

July 09, 2025

FDA to Add New Diversity Requirements for Certain Clinical Studies

News Daily News

FDA to Add New Diversity Requirements for Certain Clinical Studies

July 15, 2024

Hypertension Expert George Bakris Mourned by Colleagues and Friends

News Daily News

Hypertension Expert George Bakris Mourned by Colleagues and Friends

June 18, 2024

LDL Control Remains Poor in CAD Patients: NHANES

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

BP Reduction With Renal Denervation Still Evident a Decade On

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

News Daily News

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

July 08, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

News Conference News ACC 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

April 02, 2022

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

New STRENGTH Analysis Revives Omega-3 Debate

News Conference News ACC 2021

New STRENGTH Analysis Revives Omega-3 Debate

May 20, 2021

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

News Conference News SCAI 2021

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

Michael O'Riordan

May 06, 2021

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

News Daily News

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Yael L. Maxwell

April 09, 2021

News Opinion Editor's Corner

The Biggest News of 2020: TCTMD’s Top 10

December 28, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.